Subscribe To
Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific
– shieldtx potentially increases safety and developability of therapeutic antibodies for difficult ta...
November 1, 2023, 12:24 pm